HEALTH PROFESSIONAL · SOURCE READING

Targeted therapy (multikinase inhibitors)

Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Locally Advanced or Metastatic Primary Liver Cancer / Treatment Options for Locally Advanced or Metastatic Primary Liver Cancer / First-line systemic therapy

The FDA has approved two oral multikinase inhibitors, lenvatinib and sorafenib, for first-line treatment of patients with advanced HCC with well-compensated liver function who are not amenable to local therapies.

There are limited data on treatment options for patients with decompensated liver function.

Continue within this section

Lenvatinib →Sorafenib →

Preserved source evidence · Not medical advice